GlassScriptPhysician profile
Scott H Culp
NPI 1861482275
$3,226.18
in general payments reported to CMS, 2019-2025
23 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $36.54 · 2021: $160 · 2022: $127 · 2023: $710 · 2024: $913 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,902.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,086.27 | 2021-2025 | Vraylar, Ubrelvy, Synthroid |
| Pfizer INC. | $339.58 | 2021-2025 | |
| Novo Nordisk INC | $262.86 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $238.72 | 2023-2025 | Zepbound, Mounjaro |
| Corcept Therapeutics | $230.47 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $218.80 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $175.20 | 2021-2024 | Veozah |
| Bausch Health US, LLC | $149.05 | 2023-2025 | Wellbutrin, Aplenzin |
| Exact Sciences Corporation | $120.37 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $117.17 | 2023-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $59.40 | 2024-2025 | Voquezna |
| Dexcom, INC. | $38.14 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.58 | 2023 | Xifaxan, Trulance |
| Dynavax Technologies Corporation | $21.14 | 2024 | Heplisav-B |
| Axsome Therapeutics, INC. | $20.03 | 2025 | Symbravo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.03 | 2023 | Pediarix, Bexsero, Shingrix |
| Currax Pharmaceuticals LLC | $15.84 | 2025 | Contrave |
| Novartis Pharmaceuticals Corporation | $14.20 | 2022 | |
| Lundbeck LLC | $13.94 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.85 | 2022 | |
| Amarin Pharma, INC. | $13.11 | 2020 | |
| Boston Scientific Corporation | $11.98 | 2020 | |
| Allergan, INC. | $11.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Culp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.